AavantiBio
Part of Solid Biosciences
CompanyUnited States
AavantiBio develops 2 assets, the furthest preclinical (AVB-202 in Friedreich ataxia). Mostly gene therapy acting on FXN and BAG3; based in the United States.
- 2
- Assets
- Furthest stage
- Preclinical
- Raised
- $149M
- 0
- Trials
- 0
- Signals
Pipeline
2Delivers a functional frataxin gene using an AAV vector to restore mitochondrial frataxin expression.
Preclinical, Gene therapy, FXN, Friedreich ataxia
Delivers a functional BAG3 gene to restore BAG3 expression in cardiac muscle.
Preclinical, Gene therapy, BAG3, BAG3-mediated dilated cardiomyopathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Funding rounds and grants2
- Similar companies6